ArticleMolecular oncology2015

Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.

Belamy B Cheung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.